View Full Paper

Dissertation ⭐ 5.0

Scoping Review of Pharmacological Agents for Preventing Decompensation in Compensated Liver Cirrhosis Excluding Beta-Blockers

27 pages Harvard style ~7–13 mins read
  • Liver cirrhosis
  • Compensated cirrhosis
  • Hepatic decompensation
  • Pharmacological therapy
  • Scoping review
  • PRISMA
  • Statins
  • Rifaximin
  • Anticoagulants
  • SGLT2 inhibitors
  • GLP-1 receptor agonists
  • Albumin therapy
  • Portal hypertension
  • Hepatic encephalopathy
  • MELD score
  • Child-Pugh score
  • Risk of bias
  • Randomized controlled trials
  • Hepatology
  • Evidence synthesis

Abstract

<p>&lt;h2&gt;Cover Page&lt;/h2&gt;<br>&lt;p&gt;Scoping Review of Pharmacological Agents for Preventing Decompensation in Compensated Liver Cirrhosis Excluding Beta-Blockers&lt;/p&gt;<br>&lt;p&gt;Student Name&lt;/p&gt;<br>&lt;p&gt;Professor&lt;/p&gt;<br>&lt;p&gt;Course&lt;/p&gt;<br>&lt;p&gt;Institution&lt;/p&gt;<br>&lt;p&gt;Date&lt;/p&gt;</p> <p>&lt;h2&gt;List of Abbreviations&lt;/h2&gt;</p> <p>&lt;h2&gt;Overview of Pharmacological Agents for Preventing Decompensation in Compensated Liver Cirrhosis&lt;/h2&gt;</p> <p>&lt;h2&gt;Systematic Identification and Selection of Eligible Studies&lt;/h2&gt;</p> <p>&lt;h3&gt;PRISMA Flow Diagram for Study Selection&lt;/h3&gt;</p> <p>&lt;h3&gt;Summary of Included Pharmacological Intervention Studies&lt;/h3&gt;</p> <p>&lt;h3&gt;Reported Clinical Outcomes Across Pharmacological Classes&lt;/h3&gt;</p> <p>&lt;h3&gt;Risk of Bias Assessment of Included Studies&lt;/h3&gt;</p> <p>&lt;h2&gt;Critical Evaluation of Pharmacological Strategies for Preventing Hepatic Decompensation&lt;/h2&gt;</p> <p>&lt;h3&gt;Statins as Vascular Modulators in Cirrhosis Management&lt;/h3&gt;</p> <p>&lt;h3&gt;Rifaximin and Modulation of the Gut&ndash;Liver Axis&lt;/h3&gt;</p> <p>&lt;h3&gt;Systemic Immunomodulatory Effects of Long-Term Rifaximin Therapy&lt;/h3&gt;</p> <p>&lt;h3&gt;Anticoagulants for Preventing Portal Vein Thrombosis and Fibrosis Progression&lt;/h3&gt;</p> <p>&lt;h2&gt;Critical Appraisal of the Current Evidence Base&lt;/h2&gt;</p> <p>&lt;h3&gt;Methodological Strengths of Existing Research&lt;/h3&gt;</p> <p>&lt;h3&gt;Limitations and Sources of Evidence Heterogeneity&lt;/h3&gt;</p> <p>&lt;h2&gt;Research Gaps and Priorities for Future Investigation&lt;/h2&gt;</p> <p>&lt;h3&gt;Need for Long-Term Randomized Controlled Trials&lt;/h3&gt;</p> <p>&lt;h3&gt;Underrepresentation of Emerging Pharmacological Agents&lt;/h3&gt;</p> <p>&lt;h3&gt;Need for Combination Therapy and Precision Medicine Research&lt;/h3&gt;</p> <p>&lt;h2&gt;Clinical Implications for Prevention of Cirrhosis Decompensation&lt;/h2&gt;</p> <p>&lt;h3&gt;Translation of Evidence into Clinical Practice&lt;/h3&gt;</p> <p>&lt;h3&gt;Individualized Pharmacological Decision-Making&lt;/h3&gt;</p> <p>&lt;h3&gt;Safety Monitoring and Pharmacovigilance Considerations&lt;/h3&gt;</p> <p>&lt;h2&gt;Integrated Synthesis of Evidence and Future Directions&lt;/h2&gt;</p> <p>&lt;h2&gt;References&lt;/h2&gt;</p>

Ready to work with our team?

Get help in 3 simple steps — brief, match, deliver.